Search Within

Gunjan Lalitchandra Shah

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (161)
  2. Journal Article (74)
  3. Research Letter (7)
  4. Correspondence (2)
Groups
  1. Bone Marrow Transplant (244)
  2. Center for Hematologic Malignancies (244)
  3. Department of Medicine (244)
  4. Epidemiology and Biostatistics (244)
  5. Hematologic Malignancies, Division of (244)
  6. Survivorship Research (244)

More Groups

People
  1. Sergio Giralt (203)
  2. Michael Scordo (184)
  3. Sean Devlin (177)
  4. Miguel-Angel Perales (137)
  5. Parastoo Dahi (110)
  6. Heather Landau (100)

More People

Years
  1. 2025 (10)
  2. 2024 (28)
  3. 2023 (48)
  4. 2022 (31)
  5. 2021 (21)
  6. 2020 (34)

More Years

Publications
  1. Blood (73)
  2. Biology of Blood and Marrow Transplantation (44)
  3. Clinical Lymphoma, Myeloma and Leukemia (24)
  4. Bone Marrow Transplantation (17)
  5. Blood Advances (14)
  6. Transplantation and Cellular Therapy (13)

More Publications

Publishers
  1. American Society of Hematology (87)
  2. Elsevier Inc. (84)
  3. Nature Publishing Group (27)
  4. American Society of Clinical Oncology (11)
  5. Taylor & Francis Group (7)
  6. American Association for Cancer Research (5)

More Publishers

Results (244)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation
    Journal Article

    Peled, J. U.; Gomes, A. L. C.; Devlin, S. M.; Littmann, E. R.; Taur, Y.; Sung, A. D.; Weber, D.; Hashimoto, D.; Slingerland, A. E.; Slingerland, J. B.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management
    Journal Article

    Pennisi, M.; Jain, T.; Santomasso, B. D.; Mead, E.; Wudhikarn, K.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Devlin, S. M.; Batlevi, C.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Comparing gradings of immune effector cells toxicities: Application of ASTCT consensus grading system and implications for clinical management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T cell therapy in vulnerable older patients with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, J. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save